NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.
Location: United Kingdom, England, Cambridge
Employees: 11-50
Total raised: $44.66M
Founded date: 2017
Investors 6
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| 09.02.2024 | Neva SGR | nevasgr.co... |
| 17.05.2024 | LIFTT | liftt.com |
| - | Club degli... | clubdeglin... |
| - | 3B Future ... | 3bfuturehe... |
| - | Parkwalk A... | parkwalkad... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 01.02.2024 | Series B | $12.17M | - |
| 19.01.2023 | Series B | $7.4M | - |
| 15.03.2021 | Series B | $21.13M | Claris Ven... |
| 16.11.2017 | - | $3.96M | - |
Mentions in press and media 12
| Date | Title | Description |
| 22.05.2024 | NeoPhore Closes Series B Extension Round | Neophore, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, raised an undisclosed amount in Series B extension funding. Bristol Myers Squibb (NYSE: BMY) made the investment. The company intends to use the funds to exp... |
| 01.02.2024 | United Kingdom-based Neophore raises GBP 9.5 million in funding | London, United Kingdom-based small molecule neoantigen immuno-oncology company NeoPhore raised GBP 9.6 million (approx. USD 12.2 million) in a Series B extension. The round took place on January 31, 2023. Existing syndicates such as CPF, ma... |
| 01.02.2024 | NeoPhore Raises Additional £9.6M in Series B Extension Financing | NeoPhore, a London, UK-based small molecule neoantigen immuno-oncology company, raised additional £9.6M in Series B funding. The round, which brought the total amount to £31.1M, saw participation from its existing syndicate, CPF managed by ... |
| 19.01.2023 | NeoPhore Closes £6M Extension to Series B; Round to £21.5M | NeoPhore, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, raised £6M in an extension to its Series B funding, now totaling £21.5M. The investors included CRT Pioneer Fund, Claris Ventures, 2Invest, 3B Future Health ... |
| 15.03.2021 | NeoPhore announces £15.2m financing to advance DNA mismatch repair pipeline | NeoPhore announces £15.2m financing to advance DNA mismatch repair pipeline 15-03-2021 NeoPhore Limited, a small molecule neoantigen immuno-oncology company, has announced the close of a £15.2m (US $21m) Series B round. The syndicate was le... |
| 15.03.2021 | NeoPhore announces £15.2m financing to advance DNA mismatch repair pipeline | NeoPhore Limited, a small molecule neoantigen immuno-oncology company, has announced the close of a £15.2m (US $21m) Series B round. The syndicate was led by Claris Ventures and included 2Invest, 3B Future Health Fund and Astellas Venture M... |
| 12.03.2021 | NeoPhore: Cambridge startup secures £15M to develop advance drugs for treating cancer | NeoPhore is a Cambridge-based company focused on the discovery and development of novel molecule therapies to treat cancer. This is possible by stimulating the immune system. Now, the small molecule neoantigen immuno-oncology company has se... |
| 09.03.2021 | NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline | Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management |
| 09.03.2021 | NeoPhore Closes £15.2M Series B Funding Round | NeoPhore Limited, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, closed a £15.2m (US $21m) Series B funding round. The round was led by Claris Ventures with participation from 2Invest, 3B Future Health Fund and Ast... |
| 16.11.2017 | NeoPhore Raises £3M in Funding | NeoPhore Ltd, a spin out from Cambridge, UK – based PhoreMost Ltd., focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system, raised £3m in funding. Sixth Element Ca... |
Show more